Targeted pharmacologic interventions for autism: a double-blind, placebo-controlled trial of atomoxetine in children and adolescents with autism

Trial Profile

Targeted pharmacologic interventions for autism: a double-blind, placebo-controlled trial of atomoxetine in children and adolescents with autism

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 Status changed from recruiting to completed.
    • 31 Oct 2012 Planned end date changed from 1 Jul 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 26 Mar 2008 The expected completion date for this trial is now 1 Jul 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top